RAYMOND JAMES & ASSOCIATES - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 134 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2019. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$7,784,576
-14.5%
149,445
+4.0%
0.01%0.0%
Q2 2023$9,100,908
+17.5%
143,729
+0.4%
0.01%0.0%
Q1 2023$7,748,634
+1.1%
143,096
-1.2%
0.01%0.0%
Q4 2022$7,668,002
+0.4%
144,898
-11.7%
0.01%
-12.5%
Q3 2022$7,637,000
-10.6%
164,132
+9.7%
0.01%0.0%
Q2 2022$8,539,000
-6.3%
149,600
+0.4%
0.01%0.0%
Q1 2022$9,116,000
+24.6%
148,976
+6.6%
0.01%
+33.3%
Q4 2021$7,314,000
+46.4%
139,743
+4.3%
0.01%
+50.0%
Q3 2021$4,995,000
+7.8%
133,982
+18.0%
0.00%0.0%
Q2 2021$4,635,000
+64.1%
113,548
+36.4%
0.00%
+33.3%
Q1 2021$2,824,000
+7.8%
83,229
+1.1%
0.00%0.0%
Q4 2020$2,619,000
-34.4%
82,349
-47.0%
0.00%
-40.0%
Q3 2020$3,990,000
-5.8%
155,514
-5.8%
0.01%
-16.7%
Q2 2020$4,237,000
+107.5%
165,062
+24.2%
0.01%
+100.0%
Q1 2020$2,042,000
-56.0%
132,853
-1.7%
0.00%
-50.0%
Q4 2019$4,639,000
+586.2%
135,200
+49.3%
0.01%
+500.0%
Q3 2019$676,000
-38.3%
90,545
+7.2%
0.00%
-50.0%
Q2 2019$1,096,000
+31.1%
84,450
+23.0%
0.00%
+100.0%
Q1 2019$836,000
+121.2%
68,650
+106.9%
0.00%0.0%
Q4 2018$378,000
-75.4%
33,174
-53.1%
0.00%
-50.0%
Q3 2018$1,536,000
+35.4%
70,800
+10.4%
0.00%0.0%
Q2 2018$1,134,000
+11.7%
64,150
+33.0%
0.00%0.0%
Q1 2018$1,015,000
+328.3%
48,232
+195.0%
0.00%
Q4 2017$237,00016,3500.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2019
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders